...Bayer and Merck & Co.'s blockbuster hopeful Verquvo for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). In the HFrEF market basket, the drug will have to face off against Novartis' first-in-class Entresto, which currently holds preferred status for 50% of all covered lives under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 1/20/21
No comments:
Post a Comment